A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS).

ABSTRACT:

Purpose

Antivascular endothelial growth factor agents are increasingly used in diabetic macular oedema (DME); however, there are few studies exploring their use in DME in real-world settings.

Methods

POLARIS was a noninterventional, multicentre study to monitor 12-month outcomes in patients starting ranibizumab treatment in routine practices. The primary outcome was mean change in visual acuity (VA) from baseline to month 12 (last observation carried forward approach). Other outcomes included mean change in central retinal thickness (CRT) and resource utilization. Visual acuity (VA) outcomes were also stratified by country, baseline visual acuity score (VAS), sex, age and injection frequency.

Results

Outcomes were analysed from all treated patients (n = 804) and from

SUBMITTER: Stefanickova J 

PROVIDER: S-EPMC6585847 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature